Development
Thermo Fisher Scientific Inc.
TMO
$414.90
$0.17980.04%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -4.96% | 26.01% | 5.59% | -18.21% | 5.42% |
| Total Depreciation and Amortization | -1.64% | -0.23% | -0.47% | 1.30% | 1.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -223.45% | -445.24% | -63.16% | 442.86% | 172.41% |
| Change in Net Operating Assets | 19,244.44% | 98.75% | 53.16% | -247.12% | 383.92% |
| Cash from Operations | 54.23% | 56.75% | 111.25% | -79.09% | 80.02% |
| Capital Expenditure | -21.99% | -16.90% | 37.99% | 16.73% | -0.55% |
| Sale of Property, Plant, and Equipment | -83.33% | 1,550.00% | -33.33% | 0.00% | 50.00% |
| Cash Acquisitions | 100.00% | -1,834.04% | 98.26% | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 400.00% | 94.83% | -928.57% | -26.32% | 733.33% |
| Cash from Investing | 68.16% | -166.59% | 85.90% | -498.48% | 3.67% |
| Total Debt Issued | -28.56% | 484.49% | -42.26% | -70.56% | 1,652.76% |
| Total Debt Repaid | -153.15% | 22.11% | -266.73% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -200.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.74% | 0.00% | -15.38% | 0.00% | 0.85% |
| Other Financing Activities | -22.22% | 350.00% | -80.00% | 0.00% | 162.50% |
| Cash from Financing | -176.98% | 227.40% | 43.85% | -208.45% | 1,683.44% |
| Foreign Exchange rate Adjustments | 113.70% | -708.33% | 138.71% | -112.40% | 217.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -36.02% | 968.88% | 93.11% | -189.90% | 444.51% |